三氧化二砷联合或不联合α干扰素治疗复发/难治性成人T细胞白血病/淋巴瘤的治疗潜力。
Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
作者信息
Ishitsuka Kenji, Suzumiya Junji, Aoki Mikiko, Ogata Kentaro, Hara Shuuji, Tamura Kazuo
出版信息
Haematologica. 2007 May;92(5):719-20. doi: 10.3324/haematol.10703.
Arsenic trioxide (As2O3) with or without interferon-a (IFN) was given to 4 patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATLL). Treatment with As2O3 and IFN showed an encouraging response in two moderately-aggressive ATLL patients, while As2O3 alone was ineffective in two patients with very aggressive and rapidly progressing ATLL. Further studies are needed to clarify the role of As2O3 and its usefulness when combined with IFN for the treatment of ATLL.
三氧化二砷（As2O3）联合或不联合α干扰素（IFN）用于4例复发/难治性成人T细胞白血病/淋巴瘤（ATLL）患者。三氧化二砷与干扰素联合治疗在2例中度侵袭性ATLL患者中显示出令人鼓舞的反应，而单独使用三氧化二砷对2例侵袭性强且进展迅速的ATLL患者无效。需要进一步研究以阐明三氧化二砷的作用及其与干扰素联合用于治疗ATLL的有效性。
Zotero 插件